Mobile

The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4. Estudio Primo: Beneficios de Paricalcitol cápsulas sobre ...

Update Il y a 4 ans
Reference: EUCTR2007-001689-34

The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4. Estudio Primo: Beneficios de Paricalcitol cápsulas sobre la morbilidad cardíaca provocada por la insuficiencia renal en los sujetos con enfermedad renal crónica en estadios 3B/4

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To investigate the effects of paricalcitol capsules on progression or regression of LVH in subjects with Stage 3B/4 CKD compared to placebo, as assessed by comparing changes in LV Mass Index (LVMI) over 48 weeks measured by sequential cardiac magnetic resonance imaging (MRI).

Inclusion criteria

  • Stage 3B/4 chronic kidney disease (CKD) in subjects who have left ventricular hypertrophy (LVH). Insuficiencia renal crónica en estadío 3B/4 en sujetos con hipertrofia ventricular izquierda

Links